Advertisement
New Zealand markets closed
  • NZX 50

    11,946.43
    +143.15 (+1.21%)
     
  • NZD/USD

    0.5952
    +0.0016 (+0.26%)
     
  • NZD/EUR

    0.5552
    +0.0006 (+0.11%)
     
  • ALL ORDS

    7,937.50
    -0.40 (-0.01%)
     
  • ASX 200

    7,683.00
    -0.50 (-0.01%)
     
  • OIL

    83.04
    +0.23 (+0.28%)
     
  • GOLD

    2,332.80
    -5.60 (-0.24%)
     
  • NASDAQ

    17,526.80
    +55.33 (+0.32%)
     
  • FTSE

    8,080.81
    +40.43 (+0.50%)
     
  • Dow Jones

    38,460.92
    -42.77 (-0.11%)
     
  • DAX

    18,030.67
    -58.03 (-0.32%)
     
  • Hang Seng

    17,298.61
    +97.34 (+0.57%)
     
  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     
  • NZD/JPY

    92.5900
    +0.4750 (+0.52%)
     

Bluebird Bio’s Data for Lenti-D Investigational Gene Therapy

Bluebird Bio’s Data for Lenti-D Investigational Gene Therapy

Bluebird Bio (BLUE) released on September 5 its updated data from the Phase 2/3 Starbeam study evaluating the investigational Lenti-D gene therapy for the treatment of cerebral adrenoleukodystrophy (or CALD) in boys aged 17 years or less. The Phase 2/3 Starbeam study met its enrollment goal with the data reported by Bluebird Bio as of April 25. Thirty-one patients were studied, and 29 of them received Lenti-D gene therapy.